JPH02209890A - 新規なペプチド - Google Patents

新規なペプチド

Info

Publication number: JPH02209890A
Authority: JP; Japan
Prior art keywords: peptide; group; reference example; amino acid; lys
Prior art date: 1989-02-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP1028655A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0544960B2 (de

Inventor

Masao Tanihara

正夫谷原

Kiichirou Oka

岡樹　一郎

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

National Institute of Advanced Industrial Science and Technology AIST

Original Assignee

Agency of Industrial Science and Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1989-02-09

Publication date

1990-08-21

1989-02-09 Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology

1989-02-09 Priority to JP1028655A priority Critical patent/JPH02209890A/ja

1990-08-21 Publication of JPH02209890A publication Critical patent/JPH02209890A/ja

1993-07-07 Publication of JPH0544960B2 publication Critical patent/JPH0544960B2/ja

Status Granted legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 94
125000000539 amino acid group Chemical group 0.000 claims abstract description 5
125000003277 amino group Chemical group 0.000 claims abstract description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
239000000126 substance Substances 0.000 claims description 4
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 claims description 2
108010004073 cysteinylcysteine Proteins 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract description 21
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract description 21
150000001413 amino acids Chemical class 0.000 abstract description 16
229920001577 copolymer Polymers 0.000 abstract description 9
230000003100 immobilizing effect Effects 0.000 abstract description 4
239000000463 material Substances 0.000 abstract description 4
206010028417 myasthenia gravis Diseases 0.000 abstract description 4
229920000642 polymer Polymers 0.000 abstract description 4
125000006239 protecting group Chemical group 0.000 abstract description 4
102000005962 receptors Human genes 0.000 abstract description 3
108020003175 receptors Proteins 0.000 abstract description 3
125000004423 acyloxy group Chemical group 0.000 abstract description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
239000002245 particle Substances 0.000 description 51
239000003463 adsorbent Substances 0.000 description 25
239000001913 cellulose Substances 0.000 description 23
229920002678 cellulose Polymers 0.000 description 23
239000011347 resin Substances 0.000 description 23
229920005989 resin Polymers 0.000 description 23
239000000203 mixture Substances 0.000 description 21
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 18
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 17
239000004372 Polyvinyl alcohol Substances 0.000 description 17
229920002451 polyvinyl alcohol Polymers 0.000 description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
238000000034 method Methods 0.000 description 15
238000010438 heat treatment Methods 0.000 description 13
102000004196 processed proteins & peptides Human genes 0.000 description 13
229940024606 amino acid Drugs 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
239000004471 Glycine Substances 0.000 description 9
239000000969 carrier Substances 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
-1 polyethylene Polymers 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
238000006482 condensation reaction Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000005373 porous glass Substances 0.000 description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
229960005261 aspartic acid Drugs 0.000 description 5
230000007717 exclusion Effects 0.000 description 5
235000018977 lysine Nutrition 0.000 description 5
238000004007 reversed phase HPLC Methods 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
235000003704 aspartic acid Nutrition 0.000 description 4
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000012264 purified product Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000010532 solid phase synthesis reaction Methods 0.000 description 4
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
239000013256 coordination polymer Substances 0.000 description 3
238000004821 distillation Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
229960004295 valine Drugs 0.000 description 3
ACQSOZZSYSEKHC-UHFFFAOYSA-N 18-aminooctadecanoic acid Chemical compound NCCCCCCCCCCCCCCCCCC(O)=O ACQSOZZSYSEKHC-UHFFFAOYSA-N 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
210000000031 electric organ Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
229960002885 histidine Drugs 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
229960003136 leucine Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
229960002429 proline Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 2
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
AVJGGJDPWHBWGE-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxycarbonylamino]dodecanoyl 12-[(2-methylpropan-2-yl)oxycarbonylamino]dodecanoate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCNC(=O)OC(C)(C)C AVJGGJDPWHBWGE-UHFFFAOYSA-N 0.000 description 1
YGOPUOJOCXWSPK-UHFFFAOYSA-N 18-[(2-methylpropan-2-yl)oxycarbonylamino]octadecanoyl 18-[(2-methylpropan-2-yl)oxycarbonylamino]octadecanoate Chemical compound CC(C)(C)OC(=O)NCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCNC(=O)OC(C)(C)C YGOPUOJOCXWSPK-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine group Chemical group [*].[H]OC(=O)[C@@]([H])(N([H])[H])C([H])([H])SSC([C@@](C(=O)O[H])(N([H])[H])[H])([H])[H] LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical group C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
OPMNROCQHKJDAQ-FKSUSPILSA-N Loline Natural products C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
PQHNJDMCWOQAPR-UWVGGRQHSA-N [(2s)-2,6-diaminohexanoyl] (2s)-2,6-diaminohexanoate Chemical compound NCCCC[C@H](N)C(=O)OC(=O)[C@@H](N)CCCCN PQHNJDMCWOQAPR-UWVGGRQHSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 1
108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
OPMNROCQHKJDAQ-UHFFFAOYSA-N festucine Natural products C1CC2OC3C(NC)C2N1C3 OPMNROCQHKJDAQ-UHFFFAOYSA-N 0.000 description 1
238000011049 filling Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000004388 gamma ray sterilization Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000379 polypropylene carbonate Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
DHNZAMUKCDVXEM-UHFFFAOYSA-N tert-butyl n-dodecylcarbamate Chemical compound CCCCCCCCCCCCNC(=O)OC(C)(C)C DHNZAMUKCDVXEM-UHFFFAOYSA-N 0.000 description 1
230000024033 toxin binding Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

JP1028655A 1989-02-09 1989-02-09 新規なペプチド Granted JPH02209890A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP1028655A JPH02209890A (ja)	1989-02-09	1989-02-09	新規なペプチド

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP1028655A JPH02209890A (ja)	1989-02-09	1989-02-09	新規なペプチド

Publications (2)

Publication Number	Publication Date
JPH02209890A true JPH02209890A (ja)	1990-08-21
JPH0544960B2 JPH0544960B2 (de)	1993-07-07

Family

ID=12254523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1028655A Granted JPH02209890A (ja)	1989-02-09	1989-02-09	新規なペプチド

Country Status (1)

Country	Link
JP (1)	JPH02209890A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0579661B1 (de) *	1991-04-09	2000-01-05	Medical Research Council	Verzweigte peptide zum nachweis von antikörpern

1989
- 1989-02-09 JP JP1028655A patent/JPH02209890A/ja active Granted

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0579661B1 (de) *	1991-04-09	2000-01-05	Medical Research Council	Verzweigte peptide zum nachweis von antikörpern
EP0994121A3 (de) *	1991-04-09	2000-04-26	Medical Research Council	Verzweigte Peptide zum Nachweis von Antikörpern

Also Published As

Publication number	Publication date
JPH0544960B2 (de)	1993-07-07

Legal Events

Date	Code	Title	Description
2009-02-09	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
EP1435360B1 (de)	2009-08-19	Neues peptid, neues adsorbens, adsorptionseinheit und adsorptionsverfahren
WO1997026930A1 (en)	1997-07-31	Adsorbent for immunoglobulins and complexes thereof, adsorption method, and adsorption device
CA2026881A1 (en)	1990-08-09	Peptide and adsorbent thereof immobilized on carrier
US4889917A (en)	1989-12-26	Peptide
JP2807287B2 (ja)	1998-10-08	ペプチドおよびその用途
JP3329868B2 (ja)	2002-09-30	ペプチドおよびこれを担体上に固定化してなる吸着剤
US5132402A (en)	1992-07-21	Adsorbent, method for production thereof, and method for use thereof
WO2005035585A1 (ja)	2005-04-21	抗体アフィニティ担体
AU706019B2 (en)	1999-06-03	Peptide ligands which bind to von Willebrand factor
WO2001076662A1 (en)	2001-10-18	Adsorbents for dilated cardiomyopathy
JPH0544960B2 (de)	1993-07-07
CA1320794C (en)	1993-07-27	Peptide, adsorbent, method for production thereof, and method for use thereof
JP3574471B2 (ja)	2004-10-06	抗表皮細胞間抗体結合性ペプチドおよび吸着剤
JPH01230526A (ja)	1989-09-14	吸着剤およびその製造方法
JP2795747B2 (ja)	1998-09-10	ペプチドおよびこれを担体上に固定化してなる吸着剤
JP2001163897A (ja)	2001-06-19	ペプチドおよび該ペプチドを固定化した吸着材
JP2967956B2 (ja)	1999-10-25	ペプチドまたはその塩
Fassina et al.	1995	Inhibition of interleukin-2/p55 receptor subunit interaction by complementary peptides
JPH0720991B2 (ja)	1995-03-08	新規なペプチドおよびその用途
JPH07509400A (ja)	1995-10-19	吸着剤群
JPWO1990009396A1 (ja)	1991-01-10	ペプチドおよびこれを担体上に固定化してなる吸着剤
JP3391831B2 (ja)	2003-03-31	環状ペプチド
CN102234312A (zh)	2011-11-09	一种小分子配基亲和层析凝胶的制备及其应用
US4370312A (en)	1983-01-25	Decapeptide
JPH03161499A (ja)	1991-07-11	ペプチドおよびその用途